OPKO Health, Inc. (OPK)

In the past six months, OPKO Health's stock (OPK) has declined, hitting a new 1-year low in late April 2026, with a 52-week range between $0.98 and $1.60. Key events include Q1 2026 financial results reporting a net loss of $54.8 million, or $0.07 per share, with revenues of $124.2 million, missing consensus estimates due to the sale of certain BioReference assets in 2025. Q2 2026 and full-year revenue guidance were below Street estimates. The sale of BioReference Health assets to Labcorp for $237.5 million in 2024-2025 has refocused capital towards pharmaceuticals and royalty streams. As of March 31, 2026, approximately $92.0 million of OPKO's common stock had been repurchased, with about $108.0 million remaining available. Several research firms have reissued "market perform" or "sell" ratings on OPKO Health shares in early 2026, with an average rating of "Hold" and a consensus price target of $1.55.

The provided information does not explicitly detail demand seasonality for OPKO Health's products and services. The company's target market has shifted towards patients with rare diseases, endocrinologists, specialized oncology centers, and payors prioritizing precision therapies. Demand drivers for pharmaceutical products like NGENLA and Rayaldee are linked to treatment adherence and clinical efficacy, while diagnostic decision drivers include personalized medicine demand and prescriber preferences. No specific seasonal patterns were identified.

OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals, publicly traded on NASDAQ and TASE under the symbol "OPK". It operates within the Healthcare sector, specifically in the Drug Manufacturers and Medical Appliances & Equipment industries, employing a dual-pillar approach of high-complexity diagnostics and proprietary therapeutics. Major products and services include BioReference Laboratories (a clinical laboratory with a core genetic testing business and the 4Kscore Test), Rayaldee (an FDA-approved treatment for secondary hyperparathyroidism), NGENLA™ (an FDA-approved human growth hormone therapy), Varubi (a medication for chemotherapy-induced nausea), and pipeline products like hGH-CTP and a long-acting Factor VIIa drug.

OPKO Health's profitable operating businesses are located in the U.S., Mexico, Chile, Spain, Ireland, and Israel. Its marketed therapies are sold throughout the world, reaching over 40 international markets through commercial partnerships. The company's market presence within the U.S. is strongest in the Northeast and Florida.

OPKO Health positions itself as a company focused on improving patients' lives by delivering next-generation solutions for serious diseases, highlighting its management team and partnerships with companies like Pfizer and Merck. Its reputation has been influenced by financial performance and clinical advancements. Progress in its ModeX product development and a collaboration with Regeneron have generated positive sentiment. However, the Q1 2026 revenue miss and guidance below Street expectations have led to negative sentiment, contributing to the stock hitting a new 1-year low, with analyst ratings generally being "Hold" or "Sell".

The ownership structure of OPKO Health (OPK) includes individual, institutional, and insider investors. Dr. Phillip Frost, the chairman and CEO, is the largest individual shareholder, holding approximately 38.5% of the outstanding common stock. Institutional investors hold approximately 42% of the float, with major shareholders including Vanguard Group Inc. (7.2%) and BlackRock, Inc. (5.8%). Insiders hold approximately 49.40% of the company's stock, with some insider buying activity in the past three months.